Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P9YQ
|
|||
| Former ID |
DND000047
|
|||
| Drug Name |
Avotermin
|
|||
| Synonyms |
Juvista; RN-1001; SPD-538; TGF3, Renovo; RN-1, Renovo
Click to Show/Hide
|
|||
| Indication | Sarcoidosis [ICD-11: 4B20.5; ICD-10: D86.3] | Phase 3 | [1] | |
| Company |
Renovo, UK (Shire, UK)
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Transforming growth factor beta 3 (TGFB3) | Target Info | Modulator | [2] |
| Panther Pathway | TGF-beta signaling pathway | |||
| Pathway Interaction Database | Glypican 1 network | |||
| ALK1 signaling events | ||||
| TGF-beta receptor signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00742443) Juvista in Scar Revision Surgery of Disfiguring Scars. U.S. National Institutes of Health. | |||
| REF 2 | Discovery and development of avotermin (recombinant human transforming growth factor beta 3): a new class of prophylactic therapeutic for the improvement of scarring. Wound Repair Regen. 2011 Sep;19 Suppl 1:s38-48. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.